MAHWAH,
N.J., Aug. 19, 2024 /PRNewswire/ -- Glenmark
Therapeutics Inc., USA (Glenmark)
is pleased to announce it has launched1 Olopatadine
Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the
active ingredient in Pataday®2 Twice Daily Relief.
According to Nielsen® syndicated data for the latest 52 weeks'
period ending July 13, 2024, the
Pataday® Twice Daily Relief (OTC)
market3 achieved annual sales of approximately
$26.4 million*.
Commenting on the launch, Fabio
Moreno, Head – OTC Sales & Marketing, Glenmark
Pharmaceuticals Inc. said, "We are excited to announce the
launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the
growing demand for a new supplier in this category. This addition
highlights our commitment to meeting market needs and providing
high-quality over-the-counter solutions for our customers."
For product information and how to purchase, please visit:
https://glenmarkpharma-us.com/opatadine.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a
research–led, global pharmaceutical company, having a presence
across Branded, Generics, and OTC segments; with a focus on
therapeutic areas of respiratory, dermatology and oncology.
Glenmark Therapeutics Inc. is a subsidiary of Glenmark
Pharmaceuticals Ltd. The company has 11 world-class manufacturing
facilities spread across 4 continents, and operations in over 80
countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100
Companies Ranked by R&D and Pharmaceutical Sales, 2022; while
Generics Bulletin/In Vivo places it in the Top 50 Generics and
Biosimilars Companies Ranked by Sales, 2022. Glenmark's Green House
Gas (GHG) emission reduction targets have been approved in 2023 by
the Science Based Target initiative (SBTi), making it only the
second pharmaceutical company in India to achieve this. The organization has
impacted more than 3 million lives over the last decade through its
CSR interventions. For more information, visit
www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark
Pharmaceuticals) and Instagram (glenmark_pharma).
References:
1Glenmark's Olopatadine Hydrochloride Ophthalmic
Solution USP, 0.1% (OTC) is only marketed for the indications
listed in Glenmark's approved drug facts label.
2This product is not manufactured or distributed by
Alcon Laboratories, Inc., distributor of Pataday® Twice Daily
Relief, and/or Novartis AG, owner of the registered trademark
Pataday®, respectively. [Neither Alcon nor Novartis make or license
Glenmark's product.]
3Market includes brand and all available therapeutic
equivalents. Note: Nielsen syndicated data obtained by Glenmark is
only available for all approved RLD indications. Glenmark's product
is only approved for the indications listed in Glenmark's approved
label and is not marketed for all RLD indications.
*Nielsen® NIQ Discover; Syndicated Data for Period Ending
July 13, 2024
Logo:
https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/glenmark-therapeutics-inc-usa-launches-olopatadine-hydrochloride-ophthalmic-solution-usp-0-1-otc-302225295.html
SOURCE Glenmark Pharmaceuticals Ltd.